Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

442.13 +6.20 (+1.42%)
Streaming Delayed Price Updated: 1:57 PM EDT, May 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
73 74 Next >
News headline image
3 No-Brainer Stocks to Buy in May ↗
These great stocks are great picks for investors as spring winds down. 
Via The Motley Fool
News headline image
3 Biotech Stocks With the Potential to Make You an Overnight Millionaire ↗
Don’t miss out on these stocks that could rock your portfolio with massive growth following FDA approvals and breakthrough treatments. 
Via InvestorPlace
News headline image
A Week Of Fast-Moving Stocks Ahead: Disney, Toyota, Ferrari, Constellation ↗
Earnings season moves into final innings, some fast-moving names led by Disney, Ferrari and Constellation report. 
Via Investor's Business Daily
News headline image
Shhh! 3 Secret Gene Editing Stocks Flying Below Wall Street’s Radar ↗
The gene editing stocks are worth tuning into as some investors out there discount their innovative, albeit early-stage pipelines. 
Via InvestorPlace
News headline image
3 Growth Stocks You’ll Kick Yourself for Not Buying Today ↗
Netflix, Intuit, and Vertex Pharmaceuticals are three growth stocks to buy, each positioned for significant market share and returns. 
Via InvestorPlace
News headline image
(VRTX) - Analyzing Vertex Pharmaceuticals's Short Interest ↗
 
Via Benzinga
News headline image
2 Fantastic Growth Stocks to Buy Right Now ↗
Don't overlook these high-growth businesses. 
Via The Motley Fool
News headline image
Shhh! 3 Secret Pharma Stocks Flying Below Wall Street’s Radar ↗
Discover three under-the-radar pharma stocks poised for significant growth in 2024. Explore their product pipelines and potential gains. 
Via InvestorPlace
News headline image
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 10 Years ↗
 
Via Benzinga
News headline image
2 Top Growth Stocks to Buy Right Now and Hold Forever ↗
These healthcare stocks can provide enviable long-term portfolio growth. 
Via The Motley Fool
News headline image
Want $1 Million in Retirement? 3 Stocks to Buy Now And Hold for Decades. ↗
These three should have a lot of room to run. 
Via The Motley Fool
News headline image
$100B Vertex Pharma Working To Recreate $10B Cystic Fibrosis Success - This Time Focused On Pain Management Drugs ↗
Unlock Vertex Pharmaceuticals' pioneering treatments, from the groundbreaking Trikafta for cystic fibrosis to the promising non-opioid painkillers. 
Via Benzinga
News headline image
Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon. ↗
Good news could be just around the corner for two drugmakers not named Novo Nordisk. 
Via The Motley Fool
News headline image
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $6,000 Today ↗
 
Via Benzinga
News headline image
The Analyst Landscape: 16 Takes On Vertex Pharmaceuticals ↗
 
Via Benzinga
News headline image
Vertex Pharmaceuticals Just Made 2 Big Moves. Is the Stock a Buy? ↗
Vertex is broadening its portfolio. 
Via The Motley Fool
News headline image
Making Sense of Amazon CEO Andy Jassy's Latest Letter ↗
And that's just part of the interesting news for investors to dig into. 
Via The Motley Fool
News headline image
If You'd Invested $10,000 in Vertex Pharmaceuticals 5 Years Ago, Here's How Much You'd Have Today ↗
Could Vertex's growth story continue? 
Via The Motley Fool
News headline image
Looking for Once-in-a-Generation Investment Opportunities? Here Are 3 Magnificent Stocks to Buy Right Now ↗
These stocks could be near major inflection points. 
Via The Motley Fool
News headline image
2 Everlasting Big Pharma Stocks to Buy Today and Hold Forever ↗
These stocks probably won't be getting much cheaper. 
Via The Motley Fool
News headline image
3 Relatively Safe Growth Stocks You Can Buy and Hold ↗
Low risk and high-reward potential? These stocks could offer both. 
Via The Motley Fool
News headline image
3 Biotech Stocks Set to Double by 2028 ↗
These are three of the top biotech stocks set to double by 2028. Add them to your portfolio to maximize your potential gains. 
Via InvestorPlace
News headline image
Is Vertex Pharmaceuticals Stock a Millionaire Maker? ↗
Does this pharma stock have the potential to turn a $25,000 investment into seven figures or more? 
Via The Motley Fool
News headline image
Tesla To $123? Here Are 10 Top Analyst Forecasts For Thursday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
News headline image
Does This Acquisition Make Vertex Pharmaceuticals Stock a Buy? ↗
The biotech just added another potential growth driver to its pipeline. 
Via The Motley Fool
News headline image
Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Here's (at Least) 1 new Reason to Buy Vertex Pharmaceuticals Stock ↗
Vertex just laid claim to an asset that might be very valuable. 
Via The Motley Fool
News headline image
Could This Stock Be the Next Biotech Buyout? ↗
Vertex Pharmaceuticals' $4.9 billion purchase of Alpine Immune Sciences probably won't be the last acquisition of a company focused on kidney disease. 
Via The Motley Fool
News headline image
Stock Market Sends Mixed Signals; Nvidia, Inflation, Mideast Fears In Focus: Weekly Review ↗
The stock market gave some bullish signs, with Nvidia rebounding, but the indexes generally fell for the week on inflation and Mideast fears. 
Via Investor's Business Daily
Topics Economy
News headline image
Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact ↗
Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion, expanding into nephrology with promising APOL1-mediated kidney disease treatments. Analysts foresee significant revenue growth... 
Via Benzinga
< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
73 74 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.